$BEAT

HeartBeam, Inc. (BEAT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

HeartBeam, Inc. (BEAT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.2 3 ea029531801ex10-2.htm TRANSACTION BONUS AGREEMENT, DATED JUNE 15, 2026, BY AND BETWEEN HEARTBEAM, INC. AND BRANISLAV VAJDIC Exhibit 10.2 B Vajdic Performance Award 6.2026 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT

Original reporting
Published Jun 22, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$BEAT
Neutral
medium confidence
Mentioned
$BEAT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BEATNeutralLow
01

Why it matters

The newest concrete information is the RSU grant size (2.8M) and its vesting conditions: performance milestones over a defined period, plus service-based vesting and acceleration tied to qualifying termination and change in control definitions.

02

Market read

This is primarily a governance/compensation disclosure; it is unlikely to change near-term valuation absent additional operational or financial catalysts.

03

What to watch

Traders should still scan for any concurrent director/officer departures or appointments in the same 8-K items, since those can be more market-relevant than the RSU terms themselves.

Relevance 6/10Novelty 4/10Timing: after-hours SEC filing (8-K filed 2026-06-22)

Background

The article is an SEC Form 8-K (Item 5.02) for HeartBeam, describing departure/election/appointment and compensatory arrangements, including a transaction bonus/RSU award agreement.

Company-level read

Ticker impact

$BEATNeutralMedium confidence
Context

HeartBeam filed an 8-K detailing a June 15, 2026 RSU performance award and compensatory arrangements for director/officer Branislav Vajdic.

Expected impact

Limited near-term impact; any effect is likely indirect via governance/retention optics rather than fundamentals.

Evidence & confidence

This is a routine SEC 8-K compensation disclosure with no explicit operational or financial guidance, but it can affect expectations around retention and incentive alignment.

Market effects

Minimal; executive-compensation mechanics typically do not reset sector expectations.

None indicated.

None indicated.

Counterpoint

Because the disclosure is compensation-structure only (no new business milestone, trial result, or guidance), it may not warrant any trading response beyond routine governance noise.

Key entities

  • HeartBeam, Inc.

    Subject of the SEC 8-K; disclosed RSU/compensation terms for Branislav Vajdic.

  • Branislav Vajdic

    Participant in the June 15, 2026 RSU award agreement; vesting depends on performance milestones and service/termination conditions.

Related articles

$BEATMedAI 8/10

Heartbeam stock rating held at Neutral by H.C. Wainwright on FDA news

H.C. Wainwright maintained a Neutral rating on Heartbeam Inc. (BEAT) after its HeartBeam System received FDA Breakthrough Device designation. The stock rose 78% to $0.65, with a market cap of $36.86M. The designation, based on ALIGN-ACS study data, expedites Medicare coverage. BEAT reported a Q2 EPS of -$1.10, missing estimates by $1.01, and plans a $25M equity offering.

$BEATHighAI 8/10

Why is Heartbeam stock surging today?

HeartBeam's stock rose 56.6% after the FDA granted Breakthrough Device Designation for its HeartBeam System, a tool for evaluating potential heart attacks. The designation was granted in 30 days, ahead of the standard 60-day review period. HeartBeam estimates the heart attack assessment market at $15 billion, with a broader cardiac platform opportunity exceeding $40 billion. The NASDAQ and S&P 500 also saw modest gains.

$BEATHighAI 9/10

HeartBeam stock soars on FDA breakthrough designation

HeartBeam Inc (BEAT) shares rose 90% after the FDA granted Breakthrough Device Designation for its at-home heart attack assessment tool. The designation accelerates FDA review and opens expedited Medicare coverage pathways. HeartBeam estimates the heart attack market opportunity at $15 billion. The company plans to seek FDA alignment on a pivotal study design and begin patient enrollment soon.

$BEATMed

Why is Heartbeam stock sliding today?

Heartbeam Inc shares fell 1.7% after hours to $0.58 after the company reported Q2 2026 results. Net loss was $0.10 per share versus a $0.09 estimate, with operating expenses of $5.1M. Heartbeam lowered full-year 2026 cash outflow guidance and said ALIGN-ACS pilot enrollment was completed early.

$PCVXHighAI 9/10

Vaxcyte prices US$1B stock, warrants and notes

Vaxcyte, Inc. (NASDAQ: PCVX) raised about US$1B through concurrent stock, warrant, and convertible-note offerings. The company plans to use proceeds for clinical trials, manufacturing, and potential U.S. launch of its pneumococcal vaccine VAX-31. Vaxcyte's shares were trading at US$56.48 on Oct. 2, before the offering.